ライフサイエンスコーパス: survival

1 currence-free, disease-specific, and overall survival.

2 hologies, in which it may influence neuronal survival.

3 rs ( 10%) and associated with poorer overall survival.

4 to poorer overall and breast cancer-specific survival.

5 n repeat numbers may optimize the chance for survival.

6 ties that are associated with poor long-term survival.

7 at mitigate homeostatic imbalance and ensure survival.

8 ect of carcinoid syndrome control on patient survival.

9 nisms, both rather associated with host cell survival.

10 high-acuity vision are both fundamental for survival.

11 AZ, whose expression independently predicted survival.

12 r substantiating a role for ST6Gal-I in cell survival.

13 inct and were associated with better overall survival.

14 CDK6 substantially improve progression-free survival.

15 val and 79% (95% CI, 63% to 89%) for overall survival.

16 d a switch from BCL2 to BCLXL-dependent cell survival.

17 signature predicted a significantly shorter survival.

18 with a profound effect on patient and graft survival.

19 C mobilization and prolonged islet allograft survival.

20 for ACC enzymes in redox regulation and cell survival.

21 IL-2 production, and enhanced activation and survival.

22 n was accompanied by a significantly reduced survival.

23 analysis of recurrence treatment modality on survival.

24 30% of the between-province heterogeneity in survival.

25 s for overall survival (OS) and CRC-specific survival.

26 outcomes, short-term mortality, and overall survival.

27 tatic expiratory mouth pressure for absolute survival.

28 d pose a threat to genome stability and cell survival.

29 ty blocked brain invasion and increased host survival.

30 lpG but not glpR significantly reduced ExPEC survival.

31 th biallelic EIF2AK4 mutations had a shorter survival.

32 sease progression and significantly extended survival.

33 and this increase is thought to promote cell survival.

34 endent on the lipid hydroperoxidase GPX4 for survival.

35 ear factor kappaB (NF-kappaB)-dependent cell survival.

36 persistent signaling supports senescent cell survival.

37 of OX40 were associated with reduced patient survival.

38 ity may define breast cancer progression and survival.

39 een racial composition in a neighborhood and survival.

40 geted IL8 shRNA inhibited BM-MSC-induced AML survival.

41 Heart improves hemodynamic variables but not survival.

42 ssociated with shorter allograft and patient survival.

43 on and possibly necessary for maintenance of survival.

44 no association between prediagnosis BMI and survival.

45 ety of proteins essential to cell growth and survival.

46 ociated with rapid relapse and short overall survival.

47 st antagonize antiviral signaling events for survival.

48 Heart doses were not associated with overall survival.

49 ent can sensitise cells to stress and impair survival.

50 wing variables as unfavourable predictors of survival.

51 ion may offer their best chance at long-term survival.

52 esis reduced tumor burden and prolonged host survival.

53 rol the pathophysiological processes of cell survival.

54 transport, a critical function for neuronal survival.

55 analysis, the cumulative difference in graft survival 1 year after transplant was 115 years, and by 5

56 Still, 5-year overall survival (89% +/- 3% vs 90% +/- 4%; Plog-rank = .64), ev

57 hresholds, the negative predictive value for survival above 1 y was 79%.

58 lomustine plus bevacizumab did not confer a survival advantage over treatment with lomustine alone i

59 , there is a high incidence of CLAD and poor survival after AMR.

60 Overall, 5-year survival after an SPM was 33.1% lower for children, 20.2

61 scularization Trial) was designed to compare survival after bilateral internal thoracic artery (BITA)

62 -I loci ("A," "B," and "C") improved overall survival after ICB compared with patients who were homoz

63 her immunopathological phenotypes, including survival after infection with coxsackievirus B3.

64 f patients who achieved pCR and disease-free survival after neoadjuvant treatment according to BRCA1

65 Patient and graft survival after pancreas transplantation are superior in

66 Survival analyses indicate that arrest effects endured u

67 haracteristics of patients were compared and survival analyses were done to evaluate the effect of in

68 Statistical methods included discrete-time survival analyses.

69 b emtansine after the second interim overall survival analysis crossed the prespecified overall survi

70 A Kaplan-Meier survival analysis evaluated survival experience between

71 ling plotting, correlation analysis, patient survival analysis, similar gene detection and dimensiona

72 2% (95% CI, 56% to 84%) for progression-free survival and 79% (95% CI, 63% to 89%) for overall surviv

73 brosis manifested a beneficial role for host survival and apoptosis resistance.

74 ide reductase A to modulate liposarcoma cell survival and ASC differentiation state.

75 Using interval-censored survival and binomial regression approaches a multi-mode

76 to explore the mechanisms that result in LSC survival and develop new therapeutic approaches.

77 Essential proteins are indispensable to the survival and development process of living organisms.

78 PERK is essential for the survival and differentiation of activated satellite cell

79 criptional mechanisms that support long-term survival and differentiation of repair cells will help i

80 group analyses, clofarabine improved overall survival and EFS for European Leukemia Net (ELN) 2010 in

81 , off-pump CABG led to lower rates of 5-year survival and event-free survival than on-pump CABG.

82 ss to forage, resulting in starvation, lower survival and fecundity.

83 vascular remodeling is crucial to ensure the survival and function of engrafted islets.

84 ence life-history parameters such as growth, survival and future fecundity.

85 prove blood vessel regeneration and increase survival and hematopoietic recovery after HSC transplant

86 ATP channel antagonist tolbutamide decreases survival and increases viral replication.

87 in regulating NMJ morphology and influences survival and locomotion in Drosophila.

88 odality therapy was associated with improved survival and may offer therapeutic benefit among careful

89 its associated microbiota are essential for survival and milk production, as this community is respo

90 li, including significant reductions in cell survival and myofibroblast differentiation.

91 Progression-free survival and overall survival were secondary end points.

92 dverse cardiac remodeling, thereby improving survival and quality of life among patients with MI.

93 Recurrence-free survival and recurrence rates.

94 fluctuations in food abundance, to maximize survival and reproduction.

95 particular transcripts were associated with survival and showed longitudinal overexpression in subje

96 ctivity assay and indicated improved overall survival and significantly reduced rates of relapse in l

97 ces axonal TrkA levels and attenuates neuron survival and target innervation under limiting NGF (NGF(

98 Secondary end points included disease-free survival and the cumulative rate of nonsentinel-node met

99 e significant predictors of ventilation-free survival and Tw Pdi and maximal static expiratory mouth

100 their metabolism in a fashion that promotes survival and ultimately contributes to metastatic outgro

101 ess the impact of resection margin status on survival, and a regression analysis to analyze positive

102 a cell monolayer essential for photoreceptor survival, and is the leading cause of vision loss in the

103 Overall survival, disease-specific survival, and progression-free survival were the primary

104 obes and host cells is necessary for health, survival, and regulation of physiological functions loca

105 inues to provide excellent patient and graft survival, and stable renal function over 4 years.

106 regional trends in incidence, mortality, and survival, and the consequences, especially in socioecono

107 th incomplete recovery), inferior event-free survival as well as overall survival in both trials.

108 nge with maH3N2, progestin treatment reduced survival as well as the numbers and activity of H1N1- an

109 erization is effective in predicting patient survival, as well as in predicting several known histopa

110 Overall survival at 7 years was 66%.

111 glomerular filtration rate (eGFR), and graft-survival at 90 days and 1 year was analyzed.

112 IL-15 KO mice showed improved survival, attenuated hypothermia, and less proinflammato

113 Autophagy supports cell growth and survival autonomously by recycling intracellular protein

114 When compared with PCI, CABG still showed a survival benefit (hazard ratio, 0.82; 95% confidence int

115 To evaluate the survival benefit achieved through surgical resection of

116 ctionation and treatment effect, the overall survival benefit being restricted to the hyperfractionat

117 INTERPRETATION: We noted no survival benefit in men with metastatic castration-resis

118 High-flow nasal oxygen has recently shown survival benefits in unselected patients with acute resp

119 h SRS and there was no difference in overall survival between the treatment groups.

120 timate the difference in opioid relapse-free survival between XR-NTX and BUP-NX.

121 factors (10-year biochemical recurrence-free survival [bRFS], 29%; distant metastasis-free survival [

122 ration AR antagonist, enzalutamide, prolongs survival, but resistance and lethal disease eventually p

123 The unadjusted median overall survival by facility volume was: Q1: 26.9 months, Q2: 29

124 Patients and Methods We analyzed survival by smoking status among 1,037 patients from two

125 Survival by SPM status was significantly worse in younge

126 ed mTORC1 signaling in cancer cells promotes survival by suppressing endogenous DNA damage, and may c

127 To evaluate conditional disease-free survival (CDFS) for patients who underwent curative inte

128 5) improved function and recipient Lewis rat survival compared to UW solution alone.

129 nd lead to higher rates of cardioversion and survival compared with a manual strategy.

130 The preexisting DSA ABMR had superior graft survival compared with the de novo DSA ABMR (63% versus

131 ly earlier disease onset and reduced overall survival, compared to controls.

132 e instances, aphid hosts suffered additional survival costs when hosting double infections.

133 Updated survival data were correlated with clinical and molecula

134 ation and differentiation of stem cell, cell survival/death, and cellular metabolism under both physi

135 r the phase 3 stage of the trial was overall survival (defined as the time from randomisation until d

136 t predictor of overall (OS) and disease free survival (DFS) (p = 0.00001; p = 0.01, respectively).

137 There was no survival difference between PB-type cancers and PDAC (33

138 fied as low performing with relatively small survival differences compared with expected.

139 Overall survival, disease-specific survival, and progression-fre

140 Secondary end points included overall survival, distant metastasis-free survival, freedom from

141 ly significant difference in tumor burden or survival distributions compared to treatment with (+)-JQ

142 urvival [bRFS], 29%; distant metastasis-free survival [DMFS], 53%; prostate cancer-specific survival

143 st, activity was not an important control on survival during nonextinction intervals.

144 and Pho2 are required for gene induction and survival during phosphate starvation.

145 esults show that PI3K delta is essential for survival during sepsis.

146 al analysis crossed the prespecified overall survival efficacy boundary.

147 vs 90% +/- 4%; Plog-rank = .64), event-free survival (EFS; 87% +/- 3% vs 89% +/- 4%; Plog-rank = .71

148 red to manipulate cell death to limit T-cell survival (eg, autoimmunity and transplantation) or enhan

149 unity and transplantation) or enhance T-cell survival (eg, vaccination and immune deficiency).

150 A Kaplan-Meier survival analysis evaluated survival experience between the risk classes.

151 did not result in prolonged progression-free-survival, fewer toxic effects, or improved quality of li

152 fferences in disease-free and overall 3-year survival for open and MI esophagectomy.

153 o identify asymptomatic relapses and improve survival for patients is not well defined.

154 nction adenocarcinoma: Demonstrated superior survival for patients who received postoperative chemora

155 A random survival forest was trained to predict individual risk f

156 To test the ability of random survival forests, a machine learning technique, to predi

157 ed overall survival, distant metastasis-free survival, freedom from relapse, and safety.

158 al carcinoma progression and ultimately poor survival from disease.

159 Median overall survival from the start of chemotherapy was 29 months (9

160 Men had lower survival; hazard ratios and 95% confidence intervals wer

161 might enable earlier diagnosis and improved survival; however, the phenotypic characteristics and un

162 [FBG], and glycated hemoglobin [HbA1c]) and survival in all lung transplant (LTx) recipients and tho

163 ession of an SAM domain protein that confers survival in anemia.

164 ied 16 genes conditionally essential for GBS survival in blood, of which 75% were members of the caps

165 erior event-free survival as well as overall survival in both trials.

166 r impairments in locomotion, egg-laying, and survival in Caenorhabditis elegans.

167 TAK1; MAP3K7), which is associated with poor survival in HCC and interleukin-6 (IL6) expression.

168 ureus strain NCTC8325-4 attenuated bacterial survival in human whole blood ex vivo, which was associa

169 exposure accelerated metamorphosis increased survival in infected larvae.

170 tudy aimed to evaluate clinical response and survival in patients receiving de novo versus upgrade CR

171 The estimated hazard ratio for overall survival in patients with follow-up HSCT (inotuzumab ozo

172 ed survival rates and prognostic factors for survival in patients with HCM.

173 Although beta-blockers increase survival in patients with heart failure (HF), the mechan

174 G1 phase of the cell cycle and improves cell survival in response to growth-induced pressure.

175 pression, cell-cell contact abrogation, cell survival in suspension, STAT3 phosphorylation and water

176 pecific antagonist (CJ-12,255) would improve survival in the cecal ligation and puncture model of sep

177 The primary endpoint was overall survival in the intention-to-treat population and safety

178 ood transfusions are associated with shorter survival, independent of sepsis, after colon cancer rese

179 Aldosterone improved 5-day survival, invasive arterial pressure, and in vivo and ex

180 Although, as expected, their cumulative survival is low, once they survive the first month after

181 ation, but the effect of glycemic control on survival is unknown.We sought to determine the relations

182 mild stress can be beneficial for health and survival, known as hormesis.

183 alization and enhanced osteoclast-progenitor survival, leading to increased osteoclastogenesis.

184 in almost all MM patients and identified two survival markers for MM patients.

185 heavily on human or animal blood sources for survival, mating and reproduction.

186 This dynamic change in B cell survival mechanisms is unique to virus-infected cells an

187 ious proteins involved in the proliferation, survival, migration and epithelial-to-mesenchymal transi

188 ere deficiency of the ubiquitously expressed Survival Motor Neuron (SMN) protein.

189 nt with metastatic RCC with progression-free survival of > 3.9 years.

190 after OHCA treated with PAD showed a median survival of 40.0% (range, 9.1-83.3).

191 acerebral inflammatory phenotype and 9-month survival of 764 adults with TBM.

192 ange [IQR] 37-40) with 30-day posttransplant survival of 96%.

193 We identified 50 genes essential for the survival of A. baumannii in NHS, including already known

194 the KATP channel agonist pinacidil increases survival of bees while decreasing viral replication foll

195 tumor lesions and significantly prolongs the survival of brain tumor-bearing mice.

196 oring is associated with improved functional survival of children with severe TBI.

197 from metastases and was associated with poor survival of colon cancer patients.

198 important role in tumorigenic potential and survival of human colorectal CSCs by epigenetically acti

199 expression and nerve density, and increased survival of LSL-Kras(+/G12D);LSL-Trp53(+/R172H);Pdx1-Cre

200 rotein tau regulates the differentiation and survival of mDANs during embryonic developmental stages.

201 GDNF) promotes the function, plasticity, and survival of midbrain dopaminergic neurons, the dysfuncti

202 scular Atrophy (SMA) is caused by diminished Survival of Motor Neuron (SMN) protein, leading to neuro

203 e shunt, isocitrate lyase (ICL), may mediate survival of Mtb during the acute and chronic phases of i

204 her explore the clinical characteristics and survival of patients with ACOS identified in a real-life

205 ohort study, comorbidities influenced 1-year survival of patients with AML, and comorbidities are bes

206 Purpose Limited data are available on the survival of patients with breast cancer with preexisting

207 allele burden, and ruxolitinib might extend survival of patients with higher-risk myelofibrosis.

208 vel was associated with shorter disease-free survival of patients with TNBC.

209 of PKM2 deletion on baseline functioning and survival of photoreceptors over time by utilizing a phot

210 ces chemo-radiotherapy efficacy and improves survival of rats and mice orthotopically implanted with

211 al drug resistance mechanisms underlying the survival of residual cancer 'persister' cells.

212 munities predominantly assemble by selective survival of taxa able to persist under extreme energy li

213 ed on the role of T cells in the maintenance/survival of the mature naive peripheral B cell populatio

214 tokines, which are otherwise detrimental for survival of the parasite within the infected macrophages

215 Important to the survival of this population, these disparate habitats di

216 hazard ratios (HRs) and 95% CIs for overall survival (OS) and CRC-specific survival.

217 2 arms as the primary end point and overall survival (OS) as the secondary end point.

218 Surrogates for overall survival (OS) could expedite the evaluation of new adjuv

219 d progression-free survival (PFS) or overall survival (OS) in 20 or more patients following treatment

220 s PFS; secondary end points included overall survival (OS), objective response rate, and safety.

221 ancer-specific survival [PCSS], 78%; overall survival [OS], 69%), followed by basal prostate cancers

222 The added value of the CMI in predicting survival outcomes was evaluated and compared with circul

223 gamma-OHPdG are strongly associated with low survival (P < 0.0001) and low recurrence-free survival (

224 ons, correlated with reduced recurrence-free survival (P = 0.001).

225 urvival (P < 0.0001) and low recurrence-free survival (P = 0.007).

226 rvival [DMFS], 53%; prostate cancer-specific survival [PCSS], 78%; overall survival [OS], 69%), follo

227 After 4 doses at weekly intervals, the survival period of the mice extended beyond 70 days foll

228 ies reported MRD status and progression-free survival (PFS) or overall survival (OS) in 20 or more pa

229 uring T cell priming and not during the Tmem survival phase.

230 nodes examined was associated with improved survival, plateauing at 35 LNs (HR, 0.98; 95% CI, 0.98 t

231 the incidence rate, relative risk (RR), and survival probability with respect to NLP outcomes among

232 .SIGNIFICANCE STATEMENT Among the most basic survival problems faced by animals is balancing the need

233 Corresponding increases in survival, quality-adjusted life years (QALYs), costs, an

234 in the imatinib group, the estimated overall survival rate at 10 years was 83.3%.

235 from 2000 to 2012, it was concluded that the survival rate of HLA poorly matched living donor transpl

236 e was 96.1% (95.8-96.4), and 20-year implant survival rate was 89.7% (87.5-91.5).

237 For total knee replacement, 10-year implant survival rate was 96.1% (95.8-96.4), and 20-year implant

238 The 5-year actuarial survival rate was 96.7% (95% CI, 94.1%-99.3%) for women

239 -analysis of cohort studies to assess pooled survival rates and prognostic factors for survival in pa

240 likely to offer additional benefits, because survival rates have reached a plateau.

241 Purpose Significantly improved survival rates in patients with Ewing sarcoma have raise

242 en to reflect experimentally observed thymic survival rates result in near-optimal production of T ce

243 pectively, and the estimated 10-year overall survival rates were 19.4% and 21.5%, respectively.

244 Ten-year ESRD-free survival rates were 43%, 94%, and 72% in children with I

245 Survival rates were 50% and 89% in the control and hyper

246 The 2-year and 5-year overall survival rates were 52% (95% CI, 36%-66%) and 30% (95% C

247 The estimated 10-year progression-free survival rates were 9.5% and 9.2% for the 400- and 800-m

248 rs, the 1-month, 3-month, 1-year, and 5-year survival rates were 99%, 95%, 86%, and 76%, respectively

249 their sessile nature commands adaptation for survival rather than escape from stress.

250 Adjusted survival remained significantly better across transport

251 ence of stromal co-culture or cytoprotective survival signals.

252 re essential players in bacterial growth and survival, since they are key for uptake of nutrients on

253 tance exacerbates pathogenesis; however, the survival strategy of C. difficile in the challenging gut

254 re recruited from the Shanghai Breast Cancer Survival Study, a longitudinal study of patients diagnos

255 ower rates of 5-year survival and event-free survival than on-pump CABG.

256 thm at the time of implantation had a better survival than those in refractory ventricular fibrillati

257 tent hematuria had significantly worse renal survival than those in the other three groups.

258 xpression demonstrate a significantly poorer survival than those with low expression.

259 reduction in virus titer and improvement in survival that is associated with pronounced host antivir

260 tter in distinguishing between mortality and survival (the area under the receiver operating characte

261 IR prolonged survival; the mean number of life-years per patient was

262 ssociates with tumor progression and reduced survival time of patients with metastatic colorectal can

263 e tumor therapeutic effect and elongated the survival time of the mice.

264 r expression of TRIM28 had a shorter overall survival time.

265 injected with BrdU and analyzed at different survival times) were processed for DCX, cell proliferati

266 p and palate morphogenesis and thus ensuring survival to adulthood.

267 The overall survival to hospital discharge after OHCA treated with P

268 ted with worse colon cancer disease-specific survival [(+)transfusion: hazard ratio (HR) 1.19, 95% co

269 1.87-2.76], cardiovascular disease-specific survival [(+)transfusion: HR 1.18, 95% CI 1.04-1.33; (+)

270 sis: HR 2.04, 95% CI 1.58-2.63], and overall survival [(+)transfusion: HR 1.21, 95% CI 1.14-1.29; (+)

271 Despite somewhat prolonged progression-free survival, treatment with lomustine plus bevacizumab did

272 Survival tree analysis was used to discriminate between

273 ntrols expression of genes critical for cell survival under hyperosmotic conditions.

274 ressed BMI1 protein, which promoted cellular survival under stress due to downregulation of the E3 li

275 umab compared with docetaxel (median overall survival was 13.8 months [95% CI 11.8-15.7] vs 9.6 month

276 Median progression-free survival was 2.8 months (95% CI 2.8-3.6) in the binimeti

277 ; at 24 months, the estimated probability of survival was 38.9% (95% CI 27.6-50.0) in the inotuzumab

278 3-year overall survival was 50.3% (95% CI 45.5-54.9) in the chemotherap

279 ed patients (n=372), median progression-free survival was 6.8 months (95% CI 4.9-7.1) in the buparlis

280 Poorer survival was associated with bilateral cataract surgery

281 Mouse survival was enhanced by >13days compared to controls ad

282 pe who underwent trimodality therapy, median survival was extended from 14.5 months to 23.4 months.

283 In the ITT population, overall survival was improved with atezolizumab compared with do

284 Median overall survival was not reached for treated patients overall; a

285 Thirty-day survival was not significantly different in patients who

286 tistically significant difference in overall survival was observed between the two groups (102.7 v 11

287 statistically significant negative trend in survival was observed for increasing pack-years of smoki

288 Progression-free survival was prolonged significantly in patients allocat

289 Median progression-free survival was significantly longer in the group that unde

290 Unadjusted survival was significantly worse among recipients of EG

291 Progression-free survival and overall survival were secondary end points.

292 month Kaplan-Meier estimates of disease-free survival were significantly worse for the OAC alone grou

293 ease-specific survival, and progression-free survival were the primary end points.

294 Apis colony and queen survival were unaffected.

295 of autophagy initiator beclin-1 enhanced Mtb survival, whereas rapamycin-induced autophagy increased

296 se data show no overall evidence of improved survival with Cel.

297 re was 100% (death-censored) renal allograft survival with estimated glomerular filtration rates (mL/

298 ween functional decline, muscle strength and survival with plasma creatinine were assessed.

299 s and clinical data that are associated with survival without liver transplantation at 90 and 180 day

300 This would be completely incompatible with survival without the presence of a quasi-identical dupli